nodes	percent_of_prediction	percent_of_DWPC	metapath
Pergolide—CYP2D6—Methimazole—Graves' disease	0.229	0.611	CbGbCtD
Pergolide—CYP3A4—Methimazole—Graves' disease	0.146	0.389	CbGbCtD
Pergolide—DRD5—eyelid—Graves' disease	0.085	0.602	CbGeAlD
Pergolide—Splenomegaly—Propylthiouracil—Graves' disease	0.0572	0.135	CcSEcCtD
Pergolide—Neuritis—Methimazole—Graves' disease	0.025	0.0588	CcSEcCtD
Pergolide—Neuritis—Propylthiouracil—Graves' disease	0.0213	0.05	CcSEcCtD
Pergolide—Skin ulcer—Propylthiouracil—Graves' disease	0.0204	0.048	CcSEcCtD
Pergolide—Vasculitis—Propylthiouracil—Graves' disease	0.0163	0.0383	CcSEcCtD
Pergolide—Lymphadenopathy—Methimazole—Graves' disease	0.0159	0.0374	CcSEcCtD
Pergolide—Lymphadenopathy—Propylthiouracil—Graves' disease	0.0135	0.0318	CcSEcCtD
Pergolide—Neuropathy peripheral—Methimazole—Graves' disease	0.0102	0.0241	CcSEcCtD
Pergolide—Jaundice—Methimazole—Graves' disease	0.0102	0.024	CcSEcCtD
Pergolide—Hepatitis—Methimazole—Graves' disease	0.00937	0.0221	CcSEcCtD
Pergolide—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.0087	0.0205	CcSEcCtD
Pergolide—Jaundice—Propylthiouracil—Graves' disease	0.00865	0.0204	CcSEcCtD
Pergolide—Alopecia—Methimazole—Graves' disease	0.00828	0.0195	CcSEcCtD
Pergolide—Hepatitis—Propylthiouracil—Graves' disease	0.00797	0.0188	CcSEcCtD
Pergolide—Vertigo—Methimazole—Graves' disease	0.00733	0.0173	CcSEcCtD
Pergolide—Leukopenia—Methimazole—Graves' disease	0.0073	0.0172	CcSEcCtD
Pergolide—Alopecia—Propylthiouracil—Graves' disease	0.00704	0.0166	CcSEcCtD
Pergolide—Arthralgia—Methimazole—Graves' disease	0.00694	0.0164	CcSEcCtD
Pergolide—Myalgia—Methimazole—Graves' disease	0.00694	0.0164	CcSEcCtD
Pergolide—Dysgeusia—Propylthiouracil—Graves' disease	0.00679	0.016	CcSEcCtD
Pergolide—Oedema—Methimazole—Graves' disease	0.00666	0.0157	CcSEcCtD
Pergolide—Thrombocytopenia—Methimazole—Graves' disease	0.00652	0.0153	CcSEcCtD
Pergolide—Vertigo—Propylthiouracil—Graves' disease	0.00623	0.0147	CcSEcCtD
Pergolide—Leukopenia—Propylthiouracil—Graves' disease	0.00621	0.0146	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00607	0.0143	CcSEcCtD
Pergolide—Paraesthesia—Methimazole—Graves' disease	0.00598	0.0141	CcSEcCtD
Pergolide—Somnolence—Methimazole—Graves' disease	0.00592	0.0139	CcSEcCtD
Pergolide—Myalgia—Propylthiouracil—Graves' disease	0.0059	0.0139	CcSEcCtD
Pergolide—Arthralgia—Propylthiouracil—Graves' disease	0.0059	0.0139	CcSEcCtD
Pergolide—Dyspepsia—Methimazole—Graves' disease	0.00586	0.0138	CcSEcCtD
Pergolide—HTR1D—eye—Graves' disease	0.00567	0.0402	CbGeAlD
Pergolide—Oedema—Propylthiouracil—Graves' disease	0.00566	0.0133	CcSEcCtD
Pergolide—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00554	0.0131	CcSEcCtD
Pergolide—HTR1D—connective tissue—Graves' disease	0.00547	0.0387	CbGeAlD
Pergolide—Body temperature increased—Methimazole—Graves' disease	0.00526	0.0124	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00516	0.0121	CcSEcCtD
Pergolide—Paraesthesia—Propylthiouracil—Graves' disease	0.00508	0.012	CcSEcCtD
Pergolide—Somnolence—Propylthiouracil—Graves' disease	0.00503	0.0118	CcSEcCtD
Pergolide—Dyspepsia—Propylthiouracil—Graves' disease	0.00498	0.0117	CcSEcCtD
Pergolide—Pruritus—Methimazole—Graves' disease	0.00471	0.0111	CcSEcCtD
Pergolide—Body temperature increased—Propylthiouracil—Graves' disease	0.00447	0.0105	CcSEcCtD
Pergolide—DRD2—eye—Graves' disease	0.00427	0.0303	CbGeAlD
Pergolide—Vomiting—Methimazole—Graves' disease	0.00423	0.00997	CcSEcCtD
Pergolide—Rash—Methimazole—Graves' disease	0.0042	0.00988	CcSEcCtD
Pergolide—Dermatitis—Methimazole—Graves' disease	0.00419	0.00987	CcSEcCtD
Pergolide—Headache—Methimazole—Graves' disease	0.00417	0.00982	CcSEcCtD
Pergolide—Pruritus—Propylthiouracil—Graves' disease	0.004	0.00943	CcSEcCtD
Pergolide—Nausea—Methimazole—Graves' disease	0.00395	0.00931	CcSEcCtD
Pergolide—HTR2B—adipose tissue—Graves' disease	0.0039	0.0276	CbGeAlD
Pergolide—Vomiting—Propylthiouracil—Graves' disease	0.0036	0.00847	CcSEcCtD
Pergolide—Rash—Propylthiouracil—Graves' disease	0.00357	0.0084	CcSEcCtD
Pergolide—Dermatitis—Propylthiouracil—Graves' disease	0.00357	0.0084	CcSEcCtD
Pergolide—Headache—Propylthiouracil—Graves' disease	0.00355	0.00835	CcSEcCtD
Pergolide—HTR2B—thyroid gland—Graves' disease	0.00338	0.0239	CbGeAlD
Pergolide—Nausea—Propylthiouracil—Graves' disease	0.00336	0.00792	CcSEcCtD
Pergolide—ADRA1A—adipose tissue—Graves' disease	0.00322	0.0228	CbGeAlD
Pergolide—ADRA2A—connective tissue—Graves' disease	0.00319	0.0226	CbGeAlD
Pergolide—DRD2—pituitary gland—Graves' disease	0.00317	0.0225	CbGeAlD
Pergolide—KCNH2—pituitary gland—Graves' disease	0.00312	0.0221	CbGeAlD
Pergolide—ADRA2C—pituitary gland—Graves' disease	0.00308	0.0218	CbGeAlD
Pergolide—ADRA2C—adipose tissue—Graves' disease	0.00307	0.0217	CbGeAlD
Pergolide—HTR2A—eye—Graves' disease	0.00282	0.02	CbGeAlD
Pergolide—HTR2A—connective tissue—Graves' disease	0.00271	0.0192	CbGeAlD
Pergolide—ADRA2A—pituitary gland—Graves' disease	0.00246	0.0174	CbGeAlD
Pergolide—ADRA2A—adipose tissue—Graves' disease	0.00245	0.0173	CbGeAlD
Pergolide—ADRA2A—thyroid gland—Graves' disease	0.00212	0.015	CbGeAlD
Pergolide—HTR2A—pituitary gland—Graves' disease	0.00209	0.0148	CbGeAlD
Pergolide—DRD4—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000311	0.00528	CbGpPWpGaD
Pergolide—HTR2B—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000297	0.00504	CbGpPWpGaD
Pergolide—DRD1—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.00028	0.00476	CbGpPWpGaD
Pergolide—DRD3—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000277	0.00469	CbGpPWpGaD
Pergolide—ADRA1D—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000277	0.00469	CbGpPWpGaD
Pergolide—DRD5—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000273	0.00462	CbGpPWpGaD
Pergolide—HTR1D—G alpha (i) signalling events—CXCL10—Graves' disease	0.000263	0.00446	CbGpPWpGaD
Pergolide—HTR1B—G alpha (i) signalling events—CXCL10—Graves' disease	0.000257	0.00436	CbGpPWpGaD
Pergolide—DRD4—G alpha (i) signalling events—CXCL10—Graves' disease	0.000253	0.00429	CbGpPWpGaD
Pergolide—ADRA2B—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.00025	0.00424	CbGpPWpGaD
Pergolide—HTR1D—GPCR ligand binding—TSHR—Graves' disease	0.000246	0.00417	CbGpPWpGaD
Pergolide—HTR1A—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000241	0.00409	CbGpPWpGaD
Pergolide—HTR1B—GPCR ligand binding—TSHR—Graves' disease	0.000241	0.00409	CbGpPWpGaD
Pergolide—HTR2C—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.00024	0.00407	CbGpPWpGaD
Pergolide—DRD4—GPCR ligand binding—TSHR—Graves' disease	0.000237	0.00402	CbGpPWpGaD
Pergolide—ADRA2C—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000233	0.00396	CbGpPWpGaD
Pergolide—ADRA1B—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.00023	0.00389	CbGpPWpGaD
Pergolide—HTR2B—GPCR ligand binding—TSHR—Graves' disease	0.000226	0.00384	CbGpPWpGaD
Pergolide—DRD3—G alpha (i) signalling events—CXCL10—Graves' disease	0.000225	0.00381	CbGpPWpGaD
Pergolide—DRD4—Circadian rythm related genes—FAS—Graves' disease	0.000221	0.00374	CbGpPWpGaD
Pergolide—DRD1—GPCR ligand binding—TSHR—Graves' disease	0.000214	0.00362	CbGpPWpGaD
Pergolide—DRD2—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000212	0.00359	CbGpPWpGaD
Pergolide—DRD3—GPCR ligand binding—TSHR—Graves' disease	0.000211	0.00357	CbGpPWpGaD
Pergolide—ADRA1D—GPCR ligand binding—TSHR—Graves' disease	0.000211	0.00357	CbGpPWpGaD
Pergolide—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000209	0.00354	CbGpPWpGaD
Pergolide—HTR2A—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000208	0.00353	CbGpPWpGaD
Pergolide—DRD5—GPCR ligand binding—CXCL10—Graves' disease	0.000208	0.00352	CbGpPWpGaD
Pergolide—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000205	0.00347	CbGpPWpGaD
Pergolide—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000204	0.00346	CbGpPWpGaD
Pergolide—ADRA2B—G alpha (i) signalling events—CXCL10—Graves' disease	0.000203	0.00344	CbGpPWpGaD
Pergolide—DRD4—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000201	0.00341	CbGpPWpGaD
Pergolide—DRD1—Circadian rythm related genes—FAS—Graves' disease	0.000199	0.00337	CbGpPWpGaD
Pergolide—HTR1A—G alpha (i) signalling events—CXCL10—Graves' disease	0.000196	0.00332	CbGpPWpGaD
Pergolide—DRD3—Circadian rythm related genes—FAS—Graves' disease	0.000196	0.00332	CbGpPWpGaD
Pergolide—KCNH2—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000195	0.00331	CbGpPWpGaD
Pergolide—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000192	0.00326	CbGpPWpGaD
Pergolide—ADRA2B—GPCR ligand binding—TSHR—Graves' disease	0.00019	0.00323	CbGpPWpGaD
Pergolide—ADRA2C—G alpha (i) signalling events—CXCL10—Graves' disease	0.00019	0.00322	CbGpPWpGaD
Pergolide—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.00019	0.00321	CbGpPWpGaD
Pergolide—HTR1A—GPCR ligand binding—TSHR—Graves' disease	0.000184	0.00311	CbGpPWpGaD
Pergolide—HTR2C—GPCR ligand binding—TSHR—Graves' disease	0.000183	0.0031	CbGpPWpGaD
Pergolide—DRD5—GPCR downstream signaling—TSHR—Graves' disease	0.000182	0.00308	CbGpPWpGaD
Pergolide—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000181	0.00307	CbGpPWpGaD
Pergolide—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000179	0.00303	CbGpPWpGaD
Pergolide—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000179	0.00303	CbGpPWpGaD
Pergolide—ADRA2C—GPCR ligand binding—TSHR—Graves' disease	0.000178	0.00301	CbGpPWpGaD
Pergolide—ADRA1B—GPCR ligand binding—TSHR—Graves' disease	0.000175	0.00297	CbGpPWpGaD
Pergolide—DRD2—G alpha (i) signalling events—CXCL10—Graves' disease	0.000172	0.00292	CbGpPWpGaD
Pergolide—DRD5—Signaling by GPCR—TSHR—Graves' disease	0.000165	0.0028	CbGpPWpGaD
Pergolide—ADRA2B—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	0.000163	0.00276	CbGpPWpGaD
Pergolide—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000161	0.00274	CbGpPWpGaD
Pergolide—DRD2—GPCR ligand binding—TSHR—Graves' disease	0.000161	0.00273	CbGpPWpGaD
Pergolide—HTR1D—GPCR ligand binding—CXCL10—Graves' disease	0.000159	0.0027	CbGpPWpGaD
Pergolide—HTR2A—GPCR ligand binding—TSHR—Graves' disease	0.000159	0.00269	CbGpPWpGaD
Pergolide—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000156	0.00264	CbGpPWpGaD
Pergolide—HTR1B—GPCR ligand binding—CXCL10—Graves' disease	0.000156	0.00264	CbGpPWpGaD
Pergolide—ADRA1A—GPCR ligand binding—TSHR—Graves' disease	0.000155	0.00263	CbGpPWpGaD
Pergolide—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000155	0.00263	CbGpPWpGaD
Pergolide—ADRA2A—G alpha (i) signalling events—CXCL10—Graves' disease	0.000154	0.00261	CbGpPWpGaD
Pergolide—DRD4—GPCR ligand binding—CXCL10—Graves' disease	0.000153	0.0026	CbGpPWpGaD
Pergolide—ADRA2C—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	0.000152	0.00258	CbGpPWpGaD
Pergolide—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000151	0.00256	CbGpPWpGaD
Pergolide—DRD2—Circadian rythm related genes—FAS—Graves' disease	0.00015	0.00254	CbGpPWpGaD
Pergolide—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000148	0.00252	CbGpPWpGaD
Pergolide—HTR2B—GPCR ligand binding—CXCL10—Graves' disease	0.000146	0.00248	CbGpPWpGaD
Pergolide—ADRA2A—GPCR ligand binding—TSHR—Graves' disease	0.000144	0.00245	CbGpPWpGaD
Pergolide—KCNH2—SIDS Susceptibility Pathways—TNF—Graves' disease	0.000142	0.0024	CbGpPWpGaD
Pergolide—HTR1D—GPCR downstream signaling—TSHR—Graves' disease	0.000139	0.00236	CbGpPWpGaD
Pergolide—DRD1—GPCR ligand binding—CXCL10—Graves' disease	0.000138	0.00234	CbGpPWpGaD
Pergolide—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000137	0.00232	CbGpPWpGaD
Pergolide—HTR1B—GPCR downstream signaling—TSHR—Graves' disease	0.000136	0.00231	CbGpPWpGaD
Pergolide—ADRA1D—GPCR ligand binding—CXCL10—Graves' disease	0.000136	0.00231	CbGpPWpGaD
Pergolide—DRD3—GPCR ligand binding—CXCL10—Graves' disease	0.000136	0.00231	CbGpPWpGaD
Pergolide—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000135	0.00228	CbGpPWpGaD
Pergolide—DRD4—GPCR downstream signaling—TSHR—Graves' disease	0.000134	0.00227	CbGpPWpGaD
Pergolide—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000132	0.00224	CbGpPWpGaD
Pergolide—HTR2B—GPCR downstream signaling—TSHR—Graves' disease	0.000128	0.00217	CbGpPWpGaD
Pergolide—HTR1D—Signaling by GPCR—TSHR—Graves' disease	0.000126	0.00214	CbGpPWpGaD
Pergolide—HTR1B—Signaling by GPCR—TSHR—Graves' disease	0.000124	0.0021	CbGpPWpGaD
Pergolide—ADRA2A—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	0.000124	0.0021	CbGpPWpGaD
Pergolide—ADRA2B—GPCR ligand binding—CXCL10—Graves' disease	0.000123	0.00208	CbGpPWpGaD
Pergolide—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000122	0.00208	CbGpPWpGaD
Pergolide—HTR1A—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000122	0.00207	CbGpPWpGaD
Pergolide—DRD4—Signaling by GPCR—TSHR—Graves' disease	0.000122	0.00206	CbGpPWpGaD
Pergolide—DRD1—GPCR downstream signaling—TSHR—Graves' disease	0.000121	0.00205	CbGpPWpGaD
Pergolide—ADRA1D—GPCR downstream signaling—TSHR—Graves' disease	0.000119	0.00202	CbGpPWpGaD
Pergolide—DRD3—GPCR downstream signaling—TSHR—Graves' disease	0.000119	0.00202	CbGpPWpGaD
Pergolide—HTR1A—GPCR ligand binding—CXCL10—Graves' disease	0.000119	0.00201	CbGpPWpGaD
Pergolide—HTR2C—GPCR ligand binding—CXCL10—Graves' disease	0.000118	0.002	CbGpPWpGaD
Pergolide—DRD5—GPCR downstream signaling—CXCL10—Graves' disease	0.000117	0.00199	CbGpPWpGaD
Pergolide—HTR2B—Signaling by GPCR—TSHR—Graves' disease	0.000116	0.00197	CbGpPWpGaD
Pergolide—ADRA2C—GPCR ligand binding—CXCL10—Graves' disease	0.000115	0.00195	CbGpPWpGaD
Pergolide—ADRA1B—GPCR ligand binding—CXCL10—Graves' disease	0.000113	0.00192	CbGpPWpGaD
Pergolide—DRD1—Signaling by GPCR—TSHR—Graves' disease	0.00011	0.00186	CbGpPWpGaD
Pergolide—ADRA1D—Signaling by GPCR—TSHR—Graves' disease	0.000108	0.00183	CbGpPWpGaD
Pergolide—DRD3—Signaling by GPCR—TSHR—Graves' disease	0.000108	0.00183	CbGpPWpGaD
Pergolide—ADRA2B—GPCR downstream signaling—TSHR—Graves' disease	0.000107	0.00182	CbGpPWpGaD
Pergolide—DRD5—Signaling by GPCR—CXCL10—Graves' disease	0.000107	0.00181	CbGpPWpGaD
Pergolide—HTR2A—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000106	0.00179	CbGpPWpGaD
Pergolide—DRD2—GPCR ligand binding—CXCL10—Graves' disease	0.000104	0.00177	CbGpPWpGaD
Pergolide—HTR1A—GPCR downstream signaling—TSHR—Graves' disease	0.000104	0.00176	CbGpPWpGaD
Pergolide—HTR2C—GPCR downstream signaling—TSHR—Graves' disease	0.000103	0.00175	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—GC—Graves' disease	0.000103	0.00174	CbGpPWpGaD
Pergolide—HTR2A—GPCR ligand binding—CXCL10—Graves' disease	0.000103	0.00174	CbGpPWpGaD
Pergolide—ADRA2C—GPCR downstream signaling—TSHR—Graves' disease	0.0001	0.0017	CbGpPWpGaD
Pergolide—ADRA1A—GPCR ligand binding—CXCL10—Graves' disease	0.0001	0.0017	CbGpPWpGaD
Pergolide—ADRA1B—GPCR downstream signaling—TSHR—Graves' disease	9.88e-05	0.00168	CbGpPWpGaD
Pergolide—ADRA2B—Signaling by GPCR—TSHR—Graves' disease	9.76e-05	0.00166	CbGpPWpGaD
Pergolide—DRD5—Signaling Pathways—TSHR—Graves' disease	9.74e-05	0.00165	CbGpPWpGaD
Pergolide—HTR1A—Signaling by GPCR—TSHR—Graves' disease	9.42e-05	0.0016	CbGpPWpGaD
Pergolide—HTR2C—Signaling by GPCR—TSHR—Graves' disease	9.37e-05	0.00159	CbGpPWpGaD
Pergolide—ADRA2A—GPCR ligand binding—CXCL10—Graves' disease	9.33e-05	0.00158	CbGpPWpGaD
Pergolide—ADRA2C—Signaling by GPCR—TSHR—Graves' disease	9.12e-05	0.00155	CbGpPWpGaD
Pergolide—DRD2—GPCR downstream signaling—TSHR—Graves' disease	9.11e-05	0.00155	CbGpPWpGaD
Pergolide—HTR1D—GPCR downstream signaling—CXCL10—Graves' disease	8.99e-05	0.00152	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—TSHR—Graves' disease	8.97e-05	0.00152	CbGpPWpGaD
Pergolide—DRD5—GPCR downstream signaling—IL2RA—Graves' disease	8.97e-05	0.00152	CbGpPWpGaD
Pergolide—HTR2A—GPCR downstream signaling—TSHR—Graves' disease	8.96e-05	0.00152	CbGpPWpGaD
Pergolide—HTR1A—SIDS Susceptibility Pathways—TNF—Graves' disease	8.88e-05	0.00151	CbGpPWpGaD
Pergolide—HTR1B—GPCR downstream signaling—CXCL10—Graves' disease	8.8e-05	0.00149	CbGpPWpGaD
Pergolide—ADRA1A—GPCR downstream signaling—TSHR—Graves' disease	8.78e-05	0.00149	CbGpPWpGaD
Pergolide—DRD4—GPCR downstream signaling—CXCL10—Graves' disease	8.66e-05	0.00147	CbGpPWpGaD
Pergolide—ADRA2B—Hemostasis—IL2RA—Graves' disease	8.4e-05	0.00142	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—GC—Graves' disease	8.33e-05	0.00141	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—TSHR—Graves' disease	8.27e-05	0.0014	CbGpPWpGaD
Pergolide—HTR2B—GPCR downstream signaling—CXCL10—Graves' disease	8.27e-05	0.0014	CbGpPWpGaD
Pergolide—HTR1D—Signaling by GPCR—CXCL10—Graves' disease	8.16e-05	0.00138	CbGpPWpGaD
Pergolide—ADRA2A—GPCR downstream signaling—TSHR—Graves' disease	8.16e-05	0.00138	CbGpPWpGaD
Pergolide—DRD5—Signaling by GPCR—IL2RA—Graves' disease	8.15e-05	0.00138	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—TSHR—Graves' disease	8.14e-05	0.00138	CbGpPWpGaD
Pergolide—HTR1B—Signaling by GPCR—CXCL10—Graves' disease	7.99e-05	0.00136	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—TSHR—Graves' disease	7.97e-05	0.00135	CbGpPWpGaD
Pergolide—DRD4—Signaling by GPCR—CXCL10—Graves' disease	7.87e-05	0.00133	CbGpPWpGaD
Pergolide—ADRA2C—Hemostasis—IL2RA—Graves' disease	7.85e-05	0.00133	CbGpPWpGaD
Pergolide—DRD1—GPCR downstream signaling—CXCL10—Graves' disease	7.8e-05	0.00132	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—B3GNT2—Graves' disease	7.77e-05	0.00132	CbGpPWpGaD
Pergolide—ADRA1D—GPCR downstream signaling—CXCL10—Graves' disease	7.69e-05	0.0013	CbGpPWpGaD
Pergolide—DRD3—GPCR downstream signaling—CXCL10—Graves' disease	7.69e-05	0.0013	CbGpPWpGaD
Pergolide—HTR2A—SIDS Susceptibility Pathways—TNF—Graves' disease	7.67e-05	0.0013	CbGpPWpGaD
Pergolide—HTR2B—Signaling by GPCR—CXCL10—Graves' disease	7.51e-05	0.00127	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—TSHR—Graves' disease	7.46e-05	0.00127	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—TSHR—Graves' disease	7.41e-05	0.00126	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—TSHR—Graves' disease	7.31e-05	0.00124	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—TSHR—Graves' disease	7.19e-05	0.00122	CbGpPWpGaD
Pergolide—DRD1—Signaling by GPCR—CXCL10—Graves' disease	7.08e-05	0.0012	CbGpPWpGaD
Pergolide—ADRA1D—Signaling by GPCR—CXCL10—Graves' disease	6.99e-05	0.00118	CbGpPWpGaD
Pergolide—DRD3—Signaling by GPCR—CXCL10—Graves' disease	6.99e-05	0.00118	CbGpPWpGaD
Pergolide—ADRA2B—GPCR downstream signaling—CXCL10—Graves' disease	6.95e-05	0.00118	CbGpPWpGaD
Pergolide—HTR1D—GPCR downstream signaling—IL2RA—Graves' disease	6.87e-05	0.00117	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—TSHR—Graves' disease	6.86e-05	0.00116	CbGpPWpGaD
Pergolide—HTR1B—GPCR downstream signaling—IL2RA—Graves' disease	6.73e-05	0.00114	CbGpPWpGaD
Pergolide—HTR1A—GPCR downstream signaling—CXCL10—Graves' disease	6.71e-05	0.00114	CbGpPWpGaD
Pergolide—HTR2C—GPCR downstream signaling—CXCL10—Graves' disease	6.67e-05	0.00113	CbGpPWpGaD
Pergolide—DRD4—GPCR downstream signaling—IL2RA—Graves' disease	6.62e-05	0.00112	CbGpPWpGaD
Pergolide—ADRA2C—GPCR downstream signaling—CXCL10—Graves' disease	6.49e-05	0.0011	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—TSHR—Graves' disease	6.47e-05	0.0011	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—TSHR—Graves' disease	6.39e-05	0.00108	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—TSHR—Graves' disease	6.39e-05	0.00108	CbGpPWpGaD
Pergolide—ADRA1B—GPCR downstream signaling—CXCL10—Graves' disease	6.39e-05	0.00108	CbGpPWpGaD
Pergolide—ADRA2A—Hemostasis—IL2RA—Graves' disease	6.37e-05	0.00108	CbGpPWpGaD
Pergolide—HTR2B—GPCR downstream signaling—IL2RA—Graves' disease	6.32e-05	0.00107	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—B3GNT2—Graves' disease	6.31e-05	0.00107	CbGpPWpGaD
Pergolide—ADRA2B—Signaling by GPCR—CXCL10—Graves' disease	6.31e-05	0.00107	CbGpPWpGaD
Pergolide—DRD5—Signaling Pathways—CXCL10—Graves' disease	6.3e-05	0.00107	CbGpPWpGaD
Pergolide—HTR1D—Signaling by GPCR—IL2RA—Graves' disease	6.24e-05	0.00106	CbGpPWpGaD
Pergolide—HTR1B—Signaling by GPCR—IL2RA—Graves' disease	6.11e-05	0.00104	CbGpPWpGaD
Pergolide—HTR1A—Signaling by GPCR—CXCL10—Graves' disease	6.09e-05	0.00103	CbGpPWpGaD
Pergolide—HTR2C—Signaling by GPCR—CXCL10—Graves' disease	6.06e-05	0.00103	CbGpPWpGaD
Pergolide—DRD4—Signaling by GPCR—IL2RA—Graves' disease	6.01e-05	0.00102	CbGpPWpGaD
Pergolide—DRD1—GPCR downstream signaling—IL2RA—Graves' disease	5.96e-05	0.00101	CbGpPWpGaD
Pergolide—ADRA2C—Signaling by GPCR—CXCL10—Graves' disease	5.89e-05	0.000999	CbGpPWpGaD
Pergolide—DRD2—GPCR downstream signaling—CXCL10—Graves' disease	5.89e-05	0.000998	CbGpPWpGaD
Pergolide—ADRA1D—GPCR downstream signaling—IL2RA—Graves' disease	5.88e-05	0.000997	CbGpPWpGaD
Pergolide—DRD3—GPCR downstream signaling—IL2RA—Graves' disease	5.88e-05	0.000997	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—CXCL10—Graves' disease	5.8e-05	0.000983	CbGpPWpGaD
Pergolide—HTR2A—GPCR downstream signaling—CXCL10—Graves' disease	5.79e-05	0.000982	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—TSHR—Graves' disease	5.77e-05	0.000978	CbGpPWpGaD
Pergolide—HTR2B—Signaling by GPCR—IL2RA—Graves' disease	5.74e-05	0.000973	CbGpPWpGaD
Pergolide—ADRA1A—GPCR downstream signaling—CXCL10—Graves' disease	5.67e-05	0.000962	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—TSHR—Graves' disease	5.57e-05	0.000944	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—TSHR—Graves' disease	5.54e-05	0.000939	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—GC—Graves' disease	5.43e-05	0.000921	CbGpPWpGaD
Pergolide—DRD1—Signaling by GPCR—IL2RA—Graves' disease	5.41e-05	0.000918	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—TSHR—Graves' disease	5.39e-05	0.000913	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—CXCL10—Graves' disease	5.35e-05	0.000907	CbGpPWpGaD
Pergolide—ADRA1D—Signaling by GPCR—IL2RA—Graves' disease	5.34e-05	0.000906	CbGpPWpGaD
Pergolide—DRD3—Signaling by GPCR—IL2RA—Graves' disease	5.34e-05	0.000906	CbGpPWpGaD
Pergolide—ADRA2B—GPCR downstream signaling—IL2RA—Graves' disease	5.31e-05	0.0009	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—TSHR—Graves' disease	5.3e-05	0.000899	CbGpPWpGaD
Pergolide—ADRA2A—GPCR downstream signaling—CXCL10—Graves' disease	5.27e-05	0.000894	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—CXCL10—Graves' disease	5.26e-05	0.000892	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—CXCL10—Graves' disease	5.15e-05	0.000873	CbGpPWpGaD
Pergolide—HTR1A—GPCR downstream signaling—IL2RA—Graves' disease	5.13e-05	0.000869	CbGpPWpGaD
Pergolide—HTR2C—GPCR downstream signaling—IL2RA—Graves' disease	5.1e-05	0.000865	CbGpPWpGaD
Pergolide—ADRA2C—GPCR downstream signaling—IL2RA—Graves' disease	4.96e-05	0.000841	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—TSHR—Graves' disease	4.89e-05	0.000829	CbGpPWpGaD
Pergolide—ADRA1B—GPCR downstream signaling—IL2RA—Graves' disease	4.88e-05	0.000828	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—CXCL10—Graves' disease	4.82e-05	0.000818	CbGpPWpGaD
Pergolide—ADRA2B—Signaling by GPCR—IL2RA—Graves' disease	4.82e-05	0.000818	CbGpPWpGaD
Pergolide—DRD5—Signaling Pathways—IL2RA—Graves' disease	4.81e-05	0.000816	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—TSHR—Graves' disease	4.81e-05	0.000816	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—CXCL10—Graves' disease	4.79e-05	0.000812	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—CXCL10—Graves' disease	4.72e-05	0.000801	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—TSHR—Graves' disease	4.71e-05	0.000799	CbGpPWpGaD
Pergolide—HTR1A—Signaling by GPCR—IL2RA—Graves' disease	4.65e-05	0.000789	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—CXCL10—Graves' disease	4.65e-05	0.000788	CbGpPWpGaD
Pergolide—HTR2C—Signaling by GPCR—IL2RA—Graves' disease	4.63e-05	0.000785	CbGpPWpGaD
Pergolide—ADRA2C—Signaling by GPCR—IL2RA—Graves' disease	4.5e-05	0.000764	CbGpPWpGaD
Pergolide—DRD2—GPCR downstream signaling—IL2RA—Graves' disease	4.5e-05	0.000763	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—CXCL10—Graves' disease	4.44e-05	0.000752	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—IL2RA—Graves' disease	4.43e-05	0.000752	CbGpPWpGaD
Pergolide—HTR2A—GPCR downstream signaling—IL2RA—Graves' disease	4.43e-05	0.000751	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—TSHR—Graves' disease	4.38e-05	0.000742	CbGpPWpGaD
Pergolide—ADRA1A—GPCR downstream signaling—IL2RA—Graves' disease	4.34e-05	0.000735	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—CXCL10—Graves' disease	4.18e-05	0.000709	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—CXCL10—Graves' disease	4.13e-05	0.0007	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—CXCL10—Graves' disease	4.13e-05	0.0007	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—B3GNT2—Graves' disease	4.11e-05	0.000698	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—IL2RA—Graves' disease	4.09e-05	0.000693	CbGpPWpGaD
Pergolide—ADRA2A—GPCR downstream signaling—IL2RA—Graves' disease	4.03e-05	0.000683	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—IL2RA—Graves' disease	4.02e-05	0.000682	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—IL2RA—Graves' disease	3.94e-05	0.000668	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—CXCL10—Graves' disease	3.73e-05	0.000632	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—IL2RA—Graves' disease	3.69e-05	0.000625	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—IL2RA—Graves' disease	3.66e-05	0.00062	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—IL2RA—Graves' disease	3.61e-05	0.000612	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—CXCL10—Graves' disease	3.6e-05	0.00061	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—CXCL10—Graves' disease	3.58e-05	0.000607	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—IL2RA—Graves' disease	3.55e-05	0.000602	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—GC—Graves' disease	3.55e-05	0.000602	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—CXCL10—Graves' disease	3.48e-05	0.00059	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—CXCL10—Graves' disease	3.43e-05	0.000581	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—IL2RA—Graves' disease	3.39e-05	0.000575	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—IL2RA—Graves' disease	3.2e-05	0.000542	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CXCL10—Graves' disease	3.16e-05	0.000536	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—IL2RA—Graves' disease	3.15e-05	0.000535	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—IL2RA—Graves' disease	3.15e-05	0.000535	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CXCL10—Graves' disease	3.11e-05	0.000527	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CXCL10—Graves' disease	3.04e-05	0.000516	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—IL2RA—Graves' disease	2.85e-05	0.000483	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CXCL10—Graves' disease	2.83e-05	0.000479	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—IL2RA—Graves' disease	2.75e-05	0.000466	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—IL2RA—Graves' disease	2.74e-05	0.000464	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—B3GNT2—Graves' disease	2.69e-05	0.000456	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—IL2RA—Graves' disease	2.66e-05	0.000451	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—IL2RA—Graves' disease	2.62e-05	0.000444	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—IL2RA—Graves' disease	2.41e-05	0.000409	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—IL2RA—Graves' disease	2.38e-05	0.000403	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—IL2RA—Graves' disease	2.33e-05	0.000394	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—IL2RA—Graves' disease	2.16e-05	0.000366	CbGpPWpGaD
